Durect Corporation (DRRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Durect Corporation (DRRX) has a cash flow conversion efficiency ratio of -0.447x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.76 Million) by net assets ($3.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Durect Corporation - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Durect Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read DRRX current and long-term liabilities for a breakdown of total debt and financial obligations.
Durect Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Durect Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amiad Water Systems Ltd
TA:AMD
|
0.044x |
|
Everspring Industry Co Ltd
TW:2390
|
0.010x |
|
Equus Energy Ltd
AU:EQU
|
-0.061x |
|
Inta Bina Group Bhd
KLSE:0192
|
0.047x |
|
Alliance Witan Ord
LSE:ALW
|
0.006x |
|
Global Mofy Metaverse Limited Ordinary Shares
NASDAQ:GMM
|
0.193x |
|
Cepatwawasan Group Bhd
KLSE:8982
|
0.045x |
|
Manba Finance Ltd
NSE:MANBA
|
N/A |
Annual Cash Flow Conversion Efficiency for Durect Corporation (1999–2024)
The table below shows the annual cash flow conversion efficiency of Durect Corporation from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see Durect Corporation market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.13 Million | $-19.09 Million | -2.090x | +10.21% |
| 2023-12-31 | $14.78 Million | $-34.41 Million | -2.328x | -121.32% |
| 2022-12-31 | $24.98 Million | $-26.28 Million | -1.052x | -62.89% |
| 2021-12-31 | $57.78 Million | $-37.31 Million | -0.646x | +33.07% |
| 2020-12-31 | $40.12 Million | $-38.70 Million | -0.965x | -298.68% |
| 2019-12-31 | $22.86 Million | $11.10 Million | 0.486x | +149.18% |
| 2018-12-31 | $20.00 Million | $-19.75 Million | -0.988x | -1480.00% |
| 2017-12-31 | $21.49 Million | $-1.34 Million | -0.063x | +98.09% |
| 2016-12-31 | $8.34 Million | $-27.29 Million | -3.273x | -137.01% |
| 2015-12-31 | $14.88 Million | $-20.55 Million | -1.381x | -79.96% |
| 2014-12-31 | $18.52 Million | $-14.21 Million | -0.767x | -52.62% |
| 2013-12-31 | $30.72 Million | $-15.45 Million | -0.503x | -35.85% |
| 2012-12-31 | $36.33 Million | $-13.45 Million | -0.370x | +92.60% |
| 2011-12-31 | $3.48 Million | $-17.39 Million | -5.000x | -1033.13% |
| 2010-12-31 | $14.49 Million | $7.76 Million | 0.536x | +170.31% |
| 2009-12-31 | $27.42 Million | $-20.89 Million | -0.762x | -194.20% |
| 2008-12-31 | $36.42 Million | $-9.43 Million | -0.259x | +51.04% |
| 2007-12-31 | $34.58 Million | $-18.30 Million | -0.529x | -106.69% |
| 2006-12-31 | $37.03 Million | $-9.48 Million | -0.256x | -53.89% |
| 2005-12-31 | $43.35 Million | $-7.21 Million | -0.166x | +86.23% |
| 2004-12-31 | $18.39 Million | $-22.21 Million | -1.208x | -183.08% |
| 2003-12-31 | $45.12 Million | $-19.25 Million | -0.427x | +9.82% |
| 2002-12-31 | $66.18 Million | $-31.31 Million | -0.473x | -104.69% |
| 2001-12-31 | $97.05 Million | $-22.43 Million | -0.231x | -78.92% |
| 2000-12-31 | $115.25 Million | $-14.89 Million | -0.129x | +63.18% |
| 1999-12-31 | $20.73 Million | $-7.27 Million | -0.351x | -- |
About Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more